EP4743086A2 - TREATMENT OF MYELOID DISEASES - Google Patents

TREATMENT OF MYELOID DISEASES

Info

Publication number
EP4743086A2
EP4743086A2 EP24840626.6A EP24840626A EP4743086A2 EP 4743086 A2 EP4743086 A2 EP 4743086A2 EP 24840626 A EP24840626 A EP 24840626A EP 4743086 A2 EP4743086 A2 EP 4743086A2
Authority
EP
European Patent Office
Prior art keywords
treatment
myeloid diseases
myeloid
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24840626.6A
Other languages
German (de)
French (fr)
Inventor
Virginia M Shapiro
Kay L Medina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Foundation for Medical Education and Research
Mayo Clinic in Florida
Original Assignee
Mayo Foundation for Medical Education and Research
Mayo Clinic in Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation for Medical Education and Research, Mayo Clinic in Florida filed Critical Mayo Foundation for Medical Education and Research
Publication of EP4743086A2 publication Critical patent/EP4743086A2/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
EP24840626.6A 2023-07-13 2024-07-12 TREATMENT OF MYELOID DISEASES Pending EP4743086A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363526618P 2023-07-13 2023-07-13
PCT/US2024/037775 WO2025015263A2 (en) 2023-07-13 2024-07-12 Treating myeloid disorders

Publications (1)

Publication Number Publication Date
EP4743086A2 true EP4743086A2 (en) 2026-05-20

Family

ID=94216387

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24840626.6A Pending EP4743086A2 (en) 2023-07-13 2024-07-12 TREATMENT OF MYELOID DISEASES

Country Status (2)

Country Link
EP (1) EP4743086A2 (en)
WO (1) WO2025015263A2 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41119A (en) * 2014-12-03 2017-10-10 Acceleron Pharma Inc METHODS OF TREATMENT OF MYELODYSPLASIC SYNDROMES AND SIDEROBLASTIC ANEMIA

Also Published As

Publication number Publication date
WO2025015263A3 (en) 2025-04-24
WO2025015263A2 (en) 2025-01-16

Similar Documents

Publication Publication Date Title
EP4493064A4 (en) TREATMENT OF DEPRESSION
EP4346844A4 (en) TREATMENT OF COMPLEMENT-MEDIATED DISEASES
EP4373480A4 (en) TREATMENT OF DEPRESSION
EP4352231A4 (en) TREATMENT OF ANGPTL4-RELATED DISEASES
EP4514347A4 (en) TREATMENT OF NEUROLOGICAL DISEASES
EP4392413A4 (en) TREATMENT OF NEUROINFLAMMATORY DISEASES
EP4255458A4 (en) TREATMENT OF DANON DISEASE
EP4413032A4 (en) TREATMENT OF MASTCELL-INDUCED DISEASES
EP4003299A4 (en) TREATMENT OF SKIN DISEASES WITH TOPICAL TAPINAROF-EGFR INHIBITOR COMPOSITIONS
EP4549459A4 (en) AAV drug for the treatment of angiogenesis-related fundus diseases
EP4463157C0 (en) TREATMENT OF GM2 GANGLIOSIDOSE
EP4251753A4 (en) TREATMENT OF SOS2-RELATED DISEASES AND DISORDERS
EP3866795A4 (en) TREATMENT OF NEUROLOGICAL DISEASES
EP4419504A4 (en) KDM1A inhibitors for the treatment of diseases
EP4398908A4 (en) TREATMENT OF NEUROLOGICAL DISEASES
EP4416176A4 (en) TREATMENT OF IGE-MEDIATED DISEASES
EP4508207A4 (en) TREATMENT OF ARGINASE-1 DEFICIENCY
EP4313024A4 (en) TREATMENT OF INFLAMMATORY DISEASES
EP4404931C0 (en) AZOLE COMPOUNDS FOR THE TREATMENT OF FIBROTIC DISEASES
EP4522772A4 (en) TREATMENT OF DISEASES AND DISORDERS WITH IRAK4-MODIFIING COMPOUNDS
EP4404953A4 (en) mRNA REGULON THERAPY FOR THE TREATMENT OF HAPLOINSUFFICIENT DISEASES
EP4355430A4 (en) TREATMENT OF MST1R-RELATED DISEASES AND DISORDERS
EP4514341A4 (en) TREATMENT OF NEUROLOGICAL DISEASES
EP4499608A4 (en) INDOLIZ INDERIVATES FOR THE TREATMENT OF TRPM3-MEDIATED DISEASES
EP4136110A4 (en) TREATMENT OF RESPIRATORY DISEASES

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE